Travere Therapeutics (TVTX) Stock Price, News & Analysis

Company Overview

Travere Therapeutics, formerly known as Retrophin, is a biopharmaceutical company focused on developing and commercializing therapies for rare kidney and rare metabolic diseases. Headquartered in San Diego, California, Travere concentrates on addressing significant unmet medical needs in conditions such as cystinosis, IgA nephropathy, and lipoprotein lipase deficiency. The company’s mission is to improve patient outcomes through targeted therapies that slow disease progression and alleviate debilitating symptoms.

Among its marketed products, Travere offers PROCYSBI® (cysteamine bitartrate) delayed‐release capsules for the treatment of nephropathic cystinosis, a rare genetic disorder characterized by the accumulation of cystine in various organs. Other approved therapies include CHENODAL® (chenodiol) tablets for the dissolution of gallstones in patients who cannot undergo surgery, and KYSTEXXA® (pegloticase) for patients with refractory chronic gout. Travere continues to expand its portfolio through clinical trials and regulatory filings, including investigations into treatments for kidney fibrosis and other progressive renal diseases.

Since its founding in 2013, Travere has built a leadership team with deep expertise in nephrology and rare disease development. The company’s executive team is led by Chief Executive Officer John H. Johnson, who brings over 25 years of experience in biotechnology and healthcare. The organization emphasizes collaboration with patient advocacy groups and medical experts to guide its research priorities and ensure that its therapies address real-world clinical challenges.

Travere conducts operations and clinical research across North America and Europe, leveraging strategic partnerships to facilitate market access and patient support programs. By combining scientific innovation with focused commercialization efforts, the company aims to deliver sustainable treatments that transform the standard of care for individuals living with rare kidney and metabolic disorders.

Key Stats

• Today's Range: $14.84 to $15.09
• 50-Day Range: $14.09 to $21.54
• 52-Week Range: $7.93 to $25.29
• Volume: 663,493 shs
• Average Volume: 1.62 million shs
• Market Capitalization: $1.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.14
• Consensus Rating: Moderate Buy

Travere Therapeutics Stock Analysis - MarketRank™

Travere Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 359th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Travere Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Travere Therapeutics are expected to grow in the coming year, from ($1.40) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Travere Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Travere Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Travere Therapeutics has a P/B Ratio of 19.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.14% of the float of Travere Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Travere Therapeutics has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Travere Therapeutics has recently decreased by 17.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Travere Therapeutics does not currently pay a dividend.

Dividend Growth

Travere Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.14% of the float of Travere Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Travere Therapeutics has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Travere Therapeutics has recently decreased by 17.36%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.23

News Sentiment

Travere Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Travere Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for TVTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $485,753.00 in company stock.

Percentage Held by Insiders

Only 4.06% of the stock of Travere Therapeutics is held by insiders.

TVTX Stock Analysis - Frequently Asked Questions

How have TVTX shares performed this year?

Travere Therapeutics' stock was trading at $17.42 on January 1st, 2025. Since then, TVTX stock has decreased by 13.9% and is now trading at $15.00.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its quarterly earnings results on Thursday, May, 1st. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.08. The company's quarterly revenue was up 83.3% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Walmart (WMT), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVTX
• CIK: 1438533
• Web: www.retrophin.com
• Phone: (888) 969-7879
• Fax: 302-645-1280
• Employees: 460
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.14
• High Stock Price Target: $47.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +114.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.87
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$321.55 million
• Net Margins: -82.88%
• Pretax Margin: -82.60%
• Return on Equity: -1,179.73%
• Return on Assets: -41.10%

Debt

• Debt-to-Equity Ratio: 9.46
• Current Ratio: 2.05
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $233.18 million
• Price / Sales: 5.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.76 per share
• Price / Book: 19.74

Miscellaneous

• Outstanding Shares: 88,810,000
• Free Float: 85,084,000
• Market Cap: $1.33 billion
• Optionable: Optionable
• Beta: 0.72